GAVASSO, SABRINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.684
AS - Asia 2.369
EU - Europa 1.441
AF - Africa 590
SA - Sud America 498
OC - Oceania 64
Continente sconosciuto - Info sul continente non disponibili 36
Totale 11.682
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.369
SG - Singapore 927
CN - Cina 452
BR - Brasile 306
IT - Italia 231
HK - Hong Kong 226
VN - Vietnam 144
FI - Finlandia 140
DE - Germania 132
SE - Svezia 95
NL - Olanda 87
PL - Polonia 75
GB - Regno Unito 71
FR - Francia 61
IN - India 55
RU - Federazione Russa 54
UA - Ucraina 42
ZA - Sudafrica 39
AT - Austria 34
MX - Messico 32
TR - Turchia 30
IE - Irlanda 28
IQ - Iraq 28
AE - Emirati Arabi Uniti 27
CA - Canada 27
EC - Ecuador 27
PY - Paraguay 27
ES - Italia 26
ID - Indonesia 26
AZ - Azerbaigian 24
SA - Arabia Saudita 24
AR - Argentina 23
JP - Giappone 23
DO - Repubblica Dominicana 22
EG - Egitto 22
PE - Perù 22
BJ - Benin 21
KE - Kenya 21
BG - Bulgaria 20
CZ - Repubblica Ceca 20
MY - Malesia 20
NI - Nicaragua 20
BF - Burkina Faso 19
CI - Costa d'Avorio 19
CL - Cile 19
CO - Colombia 19
KG - Kirghizistan 19
LB - Libano 19
ML - Mali 19
MN - Mongolia 19
RO - Romania 19
CY - Cipro 18
HN - Honduras 18
ME - Montenegro 18
PA - Panama 18
TW - Taiwan 18
CD - Congo 17
CW - ???statistics.table.value.countryCode.CW??? 17
GR - Grecia 17
JO - Giordania 17
NP - Nepal 17
PH - Filippine 17
PK - Pakistan 17
SD - Sudan 17
SN - Senegal 17
BE - Belgio 16
CG - Congo 16
EE - Estonia 16
KH - Cambogia 16
KR - Corea 16
LV - Lettonia 16
LY - Libia 16
MD - Moldavia 16
MU - Mauritius 16
UY - Uruguay 16
AU - Australia 15
CH - Svizzera 15
CR - Costa Rica 15
ET - Etiopia 15
GA - Gabon 15
HR - Croazia 15
IL - Israele 15
JM - Giamaica 15
MG - Madagascar 15
MZ - Mozambico 15
RS - Serbia 15
TJ - Tagikistan 15
ZM - Zambia 15
AD - Andorra 14
AO - Angola 14
CU - Cuba 14
DZ - Algeria 14
GE - Georgia 14
GF - Guiana Francese 14
GH - Ghana 14
IS - Islanda 14
LA - Repubblica Popolare Democratica del Laos 14
MW - Malawi 14
PS - Palestinian Territory 14
PT - Portogallo 14
Totale 11.037
Salva come PNG Salva come JPEG
Città #
Fairfield 924
Ashburn 602
Woodbridge 550
Singapore 511
Chandler 501
Ann Arbor 375
Houston 368
Seattle 361
Cambridge 320
Wilmington 279
Hong Kong 215
Beijing 164
Santa Clara 115
Boardman 114
Chicago 110
Los Angeles 109
Jacksonville 106
San Diego 94
Princeton 83
Helsinki 67
Des Moines 63
Medford 54
Padova 51
Ho Chi Minh City 49
Salt Lake City 46
Munich 40
Roxbury 39
Buffalo 38
New York 38
Bytom 36
Villafranca Padovana 32
Dong Ket 31
Nanjing 29
Baku 23
Tampa 23
Elk Grove Village 22
São Paulo 22
Vienna 22
Dublin 21
London 21
Cotonou 20
Dallas 20
Hanoi 20
Shenyang 20
Warsaw 20
Nairobi 19
Ulan Bator 19
Abidjan 18
Bamako 18
Brooklyn 18
Johannesburg 18
Managua 18
Milan 18
Dakar 17
Hefei 17
Ouagadougou 17
Rio de Janeiro 17
Amman 16
Montreal 16
Panama City 16
Antananarivo 15
Atlanta 15
Dushanbe 15
Falls Church 15
Hebei 15
Stockholm 15
Willemstad 15
Andorra la Vella 14
Bishkek 14
Havana 14
Kinshasa 14
Libreville 14
Lusaka 14
Montevideo 14
Phnom Penh 14
Podgorica 14
Tokyo 14
Luanda 13
Nuremberg 13
Padua 13
Riga 13
Tashkent 13
Addis Ababa 12
Bridgetown 12
Castries 12
Frankfurt am Main 12
Maputo 12
Nassau 12
Nouakchott 12
Quito 12
Reykjavik 12
San José 12
Sofia 12
Accra 11
Amsterdam 11
Asunción 11
Banjul 11
Chisinau 11
Denver 11
Khartoum 11
Totale 7.549
Salva come PNG Salva come JPEG
Nome #
Profiling plasma alterations of extracellular vesicles in patients with acutely decompensated cirrhosis and bacterial infection 266
Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: a prospective cohort study 247
X-linked thrombophilia with a mutant factor IX (factor IX Padua). 228
Dynamics of circulating microparticles in obesity after weight loss 227
Endothelial damage of the portal vein is associated with Heparin-like effect in advanced stages of cirrhosis 205
Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease 202
Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders 198
In vitro and in vivo effects of the carbon monoxide-releasing molecule, CORM-3, in the xenogeneic pig-to-primate context 198
The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study 188
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method 185
Alterations in the coagulation profile in renal pig-to-monkey xenotransplantation 182
Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis? 181
Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S 181
Platelet factor V levels in moderate to severe congenital factor V deficiency. 178
Effects of long-term administration of recombinant human protein C in xenografted primates. 178
Perioperative coagulation assessment of patients undergoing major elective orthopedic surgery 176
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events 174
Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo-coagulable and Hyper-coagulable Features 172
Factor VIIa-antithrombin complexes in patients with non-neoplastic portal vein thrombosis with and without cirrhosis. 171
Thrombin generation in patients with COVID-19 with and without thromboprophylaxis 170
Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis 169
Peculiar laboratory phenotype/ genotype relationship due to compound inherited protein C defects in a child with severe venous thromboembolism 165
Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study 165
Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis 164
Factor IX activity/antigen ratio and the risk of first unprovoked venous thromboembolism. 163
Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. 160
Factor VIIa-antithrombin complexes in children with ischemic stroke. 159
“In vitro” correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate 158
"Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. 157
Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women 153
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms 152
Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct acting antivirals 152
Partial F8 gene duplication (Factor VIII Padua) associated with high factor VIII levels and familial thrombophilia 152
Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth? 150
Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure 149
Evaluation of a procoagulant phospholipid functional assay as a routine test for measuring circulating microparticle activity. 148
Thromboelastographic evaluation of coagulative profiles in pig-to-monkey kidney xenotransplantation. 144
The haemostatic system in acromegaly: a single-centre case–control study 144
Identification of a novel frameshift mutation causing a premature stop codon in a young Nigerian man with type I antithrombin deficiency. 143
Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet! 143
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. 142
The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study 142
Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. 140
Local prothrombotic state in portal venous system in cirrhosis 140
Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants 139
Effect on thrombin generation of the "in vitro" addition of low-dose LMWH to plasma of healthy pregnant and nonpregnant women. 138
Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. 137
Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death 137
Coagulation factor XI in cirrhosis does not predict thrombo-hemorrhagic complications and hepatic decompensation 136
Reference values for thromboelastometry (ROTEM®) in cynomolgus monkeys (Macaca fascicularis). 136
Thrombin activatable fibrinolysis inhibitor in cancer patients with and without venous thromboembolism. 134
Endocytosis of exogenous factor V by ex-vivo differentiated megakaryocytes from patients with severe parahaemophilia 134
Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. 131
The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. 130
Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. 130
Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19 130
Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis 129
Similar hypercoagulable state and thrombosis risk in type Iand type III protein S-deficient individuals from families with mixed type I/IIIprotein S deficiency. 128
A protein S functional assay yields unsatisfactory results in patients with activated protein C resistance. 126
Circulating microparticles in carriers of prothrombin G20210A mutation. 126
Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study 125
Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. 124
null 122
Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections 122
Reply to "Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis" 122
Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis. 121
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study 120
Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. 117
Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants. 116
Reticulated platelets are increased and hyper-activated in patients with cirrhosis, especially those with poor outcome 115
Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis 111
More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC 106
Thrombosis and thrombophilia in children: a systematic review. 104
Role of local endothelial alterations in the pathogenesis of portal vein thrombosis in cirrhosis 103
Influence of hepatocellular carcinoma on platelet aggregation in cirrhosis 102
Whole blood thrombin generation shows a significant hypo-coagulable state in patients with decompensated cirrhosis 98
Activation of the Contact System and Intrinsic Pathway in Peripheral and Portal Venous Circulations in Liver Cirrhosis 98
Long term use of oral contraceptives without thrombosis in patients with FV Leiden polymorphism: a study of 37 patients (2 homozygous and 35 heterozygous). 88
Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. 51
Recompensation after acute decompensation in alcohol-related cirrhosis is rare and likely unrelated to platelet-poor plasma thrombin generation and fibrinolysis 26
Totale 11.773
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.033
article - articoli 36.170
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.203
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021602 0 0 0 0 0 56 39 91 110 103 105 98
2021/20221.122 56 108 159 36 53 106 57 98 62 44 109 234
2022/2023857 168 114 49 96 139 103 5 50 85 4 39 5
2023/2024379 16 70 45 48 22 45 19 10 13 20 29 42
2024/20251.887 3 124 100 64 236 60 120 149 159 76 298 498
2025/20264.163 352 582 893 1.253 906 177 0 0 0 0 0 0
Totale 11.773